Back

Exploring CRISPR-based gene editing in ATTR-CM

30 August 2026 (15:40 - 15:50)
Organised by: Logo
Congress Presentation Part of: Targeting the source: in vivo CRISPR-based gene editing for transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Open Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

4 More presentations in this session

Presentation thumbnail
Welcome and introduction
Doctor A. Masri (Portland, US)
Presentation thumbnail
Complexities of patient care in ATTR amyloidosis
Assistant Professor J. Vaishnav (Baltimore, US)
Presentation thumbnail
The utility of CRISPR gene editing in cardiology
Professor R. Witteles (Stanford, US)
Presentation thumbnail
Targeting the source: in vivo CRISPR-based gene editing for ATTR-CM - Q&A from the audience

Access the full session

Session thumbnail
Targeting the source: in vivo CRISPR-based gene editing for transthyretin amyloid cardiomyopathy (ATTR-CM)
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 15:40 CET
You may be interested in
thumbnail
Congress Session
The bigger picture: an expert assessment on the true impact of ATTR-cardiomyopathy
1 September 2024
thumbnail
Congress Session
Clinical course of specific cardiomyopathies
18 May 2025
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025
thumbnail
Congress Session
Clinical and real-world data in ATTR cardiomyopathy: reviewing their place in daily practice
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources